À¯ÀüÀÚ Ä¡·á ½ÃÀå : À¯Çüº°, º¤ÅÍ À¯Çüº°, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)
Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2025-2030
»óǰÄÚµå : 1600875
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 187 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À¯ÀüÀÚ Ä¡·á ½ÃÀåÀº 2023³â¿¡ 56¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 70¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 27.15%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 304¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

À¯ÀüÀÚ Ä¡·á´Â À¯Àü ¹°ÁúÀ» º¯Çü½ÃÄÑ Áúº´À» Ä¡·áÇϰųª ¿¹¹æÇÏ´Â Çõ½ÅÀûÀÎ ÀÇ·á Á¢±Ù¹ýÀ¸·Î, À¯Àü¼º Áúȯ, ƯÁ¤ ¾Ï, ¹ÙÀÌ·¯½º °¨¿°¿¡ ´ëóÇÏ´Â µ¥ ÀÖ¾î ¾öû³­ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çʿ伺Àº ±Ùº»ÀûÀÎ À¯ÀüÀû ¿øÀÎÀ» ´Ù·çÁö ¸øÇÏ´Â ±âÁ¸ Ä¡·á¹ýÀÇ ÇѰ迡¼­ ºñ·ÔµË´Ï´Ù. Èñ±Í À¯Àüº´ Ä¡·á, ¾Ï Ä¡·á, Ç÷¿ìº´ Ä¡·á µî¿¡ Àû¿ëµÇ¾î ȯÀÚÀÇ °á°ú¸¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â ÁÖ·Î ÀÓ»ó ¿¬±¸, º´¿ø ¹× Àü¹® Ŭ¸®´ÐÀ» Æ÷ÇÔÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 56¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 70¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 304¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 27.15%

À¯ÀüÀÚ Ä¡·á ½ÃÀåÀº À¯Àü°øÇÐÀÇ ¹ßÀü°ú R&D ÅõÀÚ Áõ°¡·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø, À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, CRISPR°ú °°Àº ±â¼ú Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å±Ô Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎ Áõ°¡¿Í ½ÃÀå ÁøÃâ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ´Â »ç¾÷ È®ÀåÀÇ ÀáÀçÀû ±âȸ·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¹ÌÃæÁ· ¼ö¿ä¿Í Á¤ºÎ Àμ¾Æ¼ºê¸¦ Ȱ¿ëÇϱâ À§ÇØ ¼Ò¾Æ ÀûÀÀÁõ°ú ½ÅÈï ½ÃÀå¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº ºñ¿ë, À±¸®Àû ¹®Á¦, ±ÔÁ¦ Àå¾Ö¹°, Á¦Á¶ º¹À⼺ µîÀÇ Á¦¾àÀ¸·Î ÀÎÇØ È®À强¿¡ ¾î·Á¿òÀ» °ÞÀ¸¸ç ½ÃÀå ÁøÀÔÀÌ Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àå±âÀûÀÎ ¾ÈÀü¼º°ú À¯È¿¼º¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Á¶»ç°¡ ÇÊ¿äÇÕ´Ï´Ù.

Çõ½ÅÀû ޱ¸´Â Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀ̱â À§ÇÑ Àü´Þ º¤ÅÍ °³¼±, °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý °³¹ß, À¯ÀüÀÚ ÆíÁýÀÇ Á¤È®¼º°ú °á°ú ¿¹ÃøÀ» À§ÇÑ AI Ȱ¿ë µîÀÇ ºÐ¾ß·Î Áý¾àµË´Ï´Ù. ½ÃÀåÀº ºü¸£°Ô ¹ßÀüÇϰí ÀÖÁö¸¸, Àü ¼¼°èÀûÀ¸·Î ´Ù¾çÇÑ ±ÔÁ¦ ¹× °¡°Ý Ã¥Á¤ ¹®Á¦·Î ÀÎÇØ ¿©ÀüÈ÷ ´ÜÆíÈ­µÇ¾î ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ±â¼úÀ» °³¼±Çϰí Ä¡·á ¹üÀ§¸¦ È®´ëÇϱâ À§ÇÑ °øµ¿ ¿¬±¸¿¡ ÅõÀÚÇÔÀ¸·Î½á ±â¾÷Àº ¼º°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ÀÓ»ó½ÃÇè°ú ÆÄÆ®³Ê½ÊÀÇ Çʿ伺Àº ²ö±â¿Í Àü·«Àû ¼±°ßÁö¸íÀÌ ¿ä±¸µÇ´Â »óȲÀ» ¹¦»çÇϰí ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ±âÁ¸ °úÁ¦¸¦ ±Øº¹ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¸é ±â¾÷Àº Çõ½ÅÀ» ÀÏÀ¸Å°°í ºñ¿ëÀ» ÃÖÀûÈ­Çϸç Àü ¼¼°èÀûÀ¸·Î À¯ÀüÀÚ Ä¡·á ¼Ö·ç¼ÇÀÇ Á¢±Ù¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

À¯ÀüÀÚÄ¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces À¯ÀüÀÚ Ä¡·á ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â À¯ÀüÀÚ Ä¡·á ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® À¯ÀüÀÚÄ¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ °æÀï»óȲ ÆÄ¾Ç

À¯ÀüÀÚÄ¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º À¯ÀüÀÚÄ¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå À¯ÀüÀÚ Ä¡·á ½ÃÀå : À¯Çüº°

Á¦7Àå À¯ÀüÀÚ Ä¡·á ½ÃÀå : º¤ÅÍ À¯Çüº°

Á¦8Àå À¯ÀüÀÚ Ä¡·á ½ÃÀå : ¿ëµµº°

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ À¯ÀüÀÚ Ä¡·á ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯ÀüÀÚ Ä¡·á ½ÃÀå

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À¯ÀüÀÚ Ä¡·á ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

±â¾÷ ¸®½ºÆ®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Gene Therapy Market was valued at USD 5.67 billion in 2023, expected to reach USD 7.05 billion in 2024, and is projected to grow at a CAGR of 27.15%, to USD 30.48 billion by 2030.

Gene therapy, a transformative medical approach aiming to treat or prevent diseases by modifying genetic material, holds immense potential in addressing inherited disorders, certain cancers, and viral infections. Its necessity arises from the limitation of traditional therapies unable to address root genetic causes. Applications include the treatment of rare genetic disorders, cancer therapy, and hemophilia, significantly enhancing patient outcomes. In terms of end-use, gene therapy primarily finds application in clinical research, hospitals, and specialty clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.67 billion
Estimated Year [2024] USD 7.05 billion
Forecast Year [2030] USD 30.48 billion
CAGR (%) 27.15%

The gene therapy market is experiencing robust growth, driven by advancements in genetic engineering and increased investment in research and development. Key growth factors include regulatory support, an increase in the prevalence of genetic diseases, and technological innovations like CRISPR. Additionally, the growing pipeline of novel therapies and strategic collaborations among market players present potential opportunities for expansion. Companies should focus on pediatric indications and emerging markets to leverage unmet needs and governmental incentives. However, limitations include high costs, ethical concerns, regulatory hurdles, and manufacturing complexities, which challenge scalability and delay market entry. Moreover, long-term safety and efficacy continue to be under scrutiny.

Innovative exploration can be concentrated in areas such as improving delivery vectors for better precision and efficiency, developing personalized medicine approaches, and utilizing AI for gene-editing precision and forecasting outcomes. The market features rapid advancements but remains fragmented due to varying global regulations and price-setting challenges. Businesses can thrive by investing in collaborative research to refine genetic technologies and expand therapeutic scopes. The necessity for rigorous clinical trials and partnerships depicts a landscape demanding persistence and strategic foresight. All in all, with a focus on overcoming existing challenges, businesses have the opportunity to innovate, optimize costs, and improve the accessibility of gene therapy solutions globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Therapy Market

The Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Therapy Market

A detailed market share analysis in the Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Cellectis, Inc., Novartis AG, Biogen Inc., AnGes, Inc., Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Astellas Gene Therapies, Sarepta Therapeutics, Inc., Uniqure N.V., Applied Genetic Technologies Corporation, Mustang Bio, Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Amgen Inc., Sangamo Therapeutics, Inc., AGC Biologics., Merck & Co., Inc., American Gene Technologies Inc., Editas Medicine, Inc., Bluebird Bio, Inc., Alnylam Pharmaceuticals, Inc., and Human Stem Cells Institute.

Market Segmentation & Coverage

This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Gene Therapy Market, by Type

7. Gene Therapy Market, by Vector Type

8. Gene Therapy Market, by Application

9. Americas Gene Therapy Market

10. Asia-Pacific Gene Therapy Market

11. Europe, Middle East & Africa Gene Therapy Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â